Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.
Oculis also said it received the Investigational New Drug application clearance from the FDA.
“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.
https://finance.yahoo.com/news/oculis-trial-shows-potential-optical-223042372.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.